Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep 3;56(3):2002182.
doi: 10.1183/13993003.02182-2020. Print 2020 Sep.

Potential of regulatory T-cell-based therapies in the management of severe COVID-19

Emmanuel Stephen-Victor  1 , Mrinmoy Das  1 , Anupama Karnam  2 , Bruno Pitard  3 , Jean-François Gautier  2   4 , Jagadeesh Bayry  5
Affiliations
Comment

Potential of regulatory T-cell-based therapies in the management of severe COVID-19

Emmanuel Stephen-Victor et al. Eur Respir J. .

Abstract

In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4+CD25+FoxP3+ regulatory T-cell-based therapies could be considered for patient management https://bit.ly/3eKqWPo

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: E. Stephen-Victor has nothing to disclose. Conflict of interest: M. Das has nothing to disclose. Conflict of interest: A. Karnam has nothing to disclose. Conflict of interest: B. Pitard has nothing to disclose. Conflict of interest: J-F. Gautier has nothing to disclose. Conflict of interest: J. Bayry reports grants from Agence Nationale de la Recherche, France (Appel Flash COVID-19-COVIMUNE and ANR-19-CE17-0021(BASIN)), outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Potential of regulatory T-cell (Treg)-based therapies in the management of severe coronavirus disease 2019 (COVID-19). Tregs and their functions are compromised in severe COVID-19 patients, engendering unrestrained immune cell activation. Dysregulated antigen-presenting cells (APCs) insinuate tissue inflammation and immunopathology by secreting inflammatory cytokines and activating a T-cell-dependent immune response. We suggest that either adoptive transfer of allogenic Tregs or use of Treg-derived molecules like cytotoxic T-lymphocyte antigen (CTLA)-4 (abatacept) might block the activation of APC and costimulatory pathways. Such therapies have the potential to curtail tissue inflammation and immunopathology, leading to better management of COVID-19 patients. IL: interleukin; TNF: tumour necrosis factor.
See this image and copyright information in PMC

Comment on

  • Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Huang C, et al. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Lancet. 2020. PMID: 31986264 Free PMC article.

References

    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. doi:10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
    1. Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci 2020; 41: 363–382. doi:10.1016/j.tips.2020.03.006 - DOI - PMC - PubMed
    1. Bonam SR, Kaveri SV, Sakuntabhai A, et al. . Adjunct immunotherapies for the management of severely ill COVID-19 patients. Cell Rep Med 2020; 1: 100016. doi:10.1016/j.xcrm.2020.100016 - DOI - PMC - PubMed
    1. Wing JB, Tanaka A, Sakaguchi S. Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity 2019; 50: 302–316. doi:10.1016/j.immuni.2019.01.020 - DOI - PubMed
    1. Arpaia N, Green JA, Moltedo B, et al. . A distinct function of regulatory T cells in tissue protection. Cell 2015; 162: 1078–1089. doi:10.1016/j.cell.2015.08.021 - DOI - PMC - PubMed